Anita Gm Stam

Anita Gm Stam

Auto-generated profile, based on publicly available information

Anita Gm Stam

Amsterdam UMC location Vrije Universiteit, Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022 in Science Immunology
Verified
Journal Article
Closed access
KPKim M. van Pul
Kim M. van Pul
JNJessica C. L. Notohardjo
Jessica C. L. Notohardjo
MFMarieke F. Fransen
Marieke F. Fransen
BKBas D. Koster
Bas D. Koster
ASAnita G. M. Stam
Anita G. M. Stam
TGTanja De Gruijl
Tanja De Gruijl
Preclinical studies show that locoregional CTLA-4 blockade is equally effective in inducing tumor eradication as systemic delivery, without the added risk of immune-related side effects. This efficacy is related to access of the CTLA-4 blocking antibodies to tumor-draining lymph nodes (TDLNs). Local delivery of anti–CTLA-4 after surgical removal of primary melanoma, before sentinel lymph node biopsy (SLNB), provides a unique setting to clinically assess the role of TDLN in the biological efficacy of locoregional CTLA-4 blockade. Here, we have evaluated the safety, tolerability, and immunomodulatory effects in the SLN and peripheral blood of a single dose of tremelimumab [a fully human immunoglobulin gamma-2 (IgG2) mAb directed against CTLA-4] in a dose range of 2 to 20 mg, injected intradermally at the tumor excision site 1 week before SLNB in 13 patients with early-stage melanoma (phase 1 trial; NCT04274816). Intradermal delivery was safe and well tolerated and induced activation of migratory dendritic cell (DC) subsets in the SLN. It also induced profound and durable decreases in regulatory T cell (T reg ) frequencies and activation of effector T cells in both SLN and peripheral blood. Moreover, systemic T cell responses against NY-ESO-1 or MART-1 were primed or boosted ( N = 7), in association with T cell activation and central memory T cell differentiation. These findings indicate that local administration of anti–CTLA-4 may offer a safe and promising adjuvant treatment strategy for patients with early-stage melanoma. Moreover, our data demonstrate a central role for TDLN in the biological efficacy of CTLA-4 blockade and support TDLN-targeted delivery methods.

1 August 2016 in Clinical Immunology
Verified
Journal Article
Open access
RBRenée C.G. de Bruin
Renée C.G. de Bruin
SLSinéad M. Lougheed
Sinéad M. Lougheed
LKLiza van der Kruk
Liza van der Kruk
ASAnita G. Stam
Anita G. Stam
EHErik Hooijberg
Erik Hooijberg
HVHans van der Vliet
Hans van der Vliet
Vγ9Vδ2-T cells constitute the predominant subset of γδ-T cells in human peripheral blood and have been shown to play an important role in antimicrobial and antitumor immune responses. Several efforts have been initiated to exploit these cells for cancer immunotherapy, e.g. by using phosphoantigens, adoptive cell transfer, and by a bispecific monoclonal antibody based approach. Here, we report the generation of a novel set of Vγ9Vδ2-T cell specific VHH (or nanobody). VHH have several advantages compared to conventional antibodies related to their small size, stability, ease of generating multispecific molecules and low immunogenicity. With high specificity and affinity, the anti-Vγ9Vδ2-T cell receptor VHHs are shown to be useful for FACS, MACS and immunocytochemistry. In addition, some VHH were found to specifically activate Vγ9Vδ2-T cells. Besides being of possible immunotherapeutic value, these single domain antibodies will be of great value in the further study of this important immune effector cell subset.

18 March 2014 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
JLJelle J Lindenberg
Jelle J Lindenberg
RVRieneke Van De Ven
Rieneke Van De Ven
DODinja Oosterhoff
Dinja Oosterhoff
CSClaudia C Sombroek
Claudia C Sombroek
SLSinéad M Lougheed
Sinéad M Lougheed
TGTanja De Gruijl
Tanja De Gruijl
Autologous tumor cell-based vaccines provide a wide range of tumor antigens and personalized neo-epitopes based on individual tumors’ unique antigenic mutanome signatures. However, tumor-derived factors may hamper in situ maturation of dendritic cells (DC) and thus interfere with the generation of effective anti-tumor immunity. As the skin is a preferred site for tumor vaccine delivery, we investigated the influence of primary colon carcinoma-derived soluble factors on the maturation state of migrating DC in a human skin explant model. Primary tumor-derived supernatants (TDSN) enhanced the phenotypic maturation state of skin-emigrated DC, resulting in an increased T-cell stimulatory ability in an allogeneic mixed leukocyte response. In case of monocyte-derived DC a similar TDSN-induced maturation induction was found to entirely depend on cyclooxygenase (COX)-regulated prostaglandins. In contrast, the increase in skin-emigrated DC maturation was completely prostaglandin-independent, as evidenced by the ina...

4 April 2023
Verified
Other
Open access
IWIris de Weerdt
Iris de Weerdt
RLRoeland Lameris
Roeland Lameris
GSGeorge L. Scheffer
George L. Scheffer
JVJana Vree
Jana Vree
RBRenate de Boer
Renate de Boer
HVHans van der Vliet
Hans van der Vliet

4 April 2023
Verified
Other
Open access
IWIris de Weerdt
Iris de Weerdt
RLRoeland Lameris
Roeland Lameris
GSGeorge L. Scheffer
George L. Scheffer
JVJana Vree
Jana Vree
RBRenate de Boer
Renate de Boer
HVHans van der Vliet
Hans van der Vliet

4 April 2023
Verified
Other
Open access
IWIris de Weerdt
Iris de Weerdt
RLRoeland Lameris
Roeland Lameris
GSGeorge L. Scheffer
George L. Scheffer
JVJana Vree
Jana Vree
RBRenate de Boer
Renate de Boer
HVHans van der Vliet
Hans van der Vliet